Validation of Models Used to Inform Colorectal Cancer Screening Guidelines

Medical Decision Making

Volumn 36, Issue 5, 2016, Pages 604-614

  Rutter, Carolyn M ^a   Knudsen, Amy B ^b   Marsh, Tracey L ^c   Doria Rose, V Paul ^d   Johnson, Eric ^e   Pabiniak, Chester ^e   Kuntz, Karen M ^f   Van Ballegooijen, Marjolein ^g   Zauber, Ann G ^h   Lansdorp Vogelaar, Iris ^g  

^a RAND CORPORATION   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e GROUP HEALTH RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF MINNESOTA   (United States)

^g ERASMUS MEDICAL CENTER   (Netherlands)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

colorectal cancer; discrete event simulation; gastroenterology; preventive medicine; simulation methods

Indexed keywords

COLORECTAL TUMOR; HUMAN; INFORMED CONSENT; MASS SCREENING; MORTALITY; PRACTICE GUIDELINE; PROCEDURES; THEORETICAL MODEL; UNITED KINGDOM; VALIDATION STUDY;

COLORECTAL NEOPLASMS; HUMANS; INFORMED CONSENT; MASS SCREENING; MODELS, THEORETICAL; PRACTICE GUIDELINES AS TOPIC; UNITED KINGDOM;

EID: 84971356846     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X15622642     Document Type: Article

References (46)

1. Lansdorp-Vogelaar I, Kuntz KM, Knudsen AB, Wilschut JA, Zauber AG, van Ballegooijen M,. Stool DNA testing to screen for colorectal cancer in the Medicare population: A cost-effectiveness analysis. Ann Intern Med. 2010; 153 (6): 368-77
2. Knudsen AB, Lansdorp-Vogelaar I, Rutter CM, et al. Cost-effectiveness of computed tomographic colonography screening for colorectal cancer in the Medicare population. J Natl Cancer Inst. 2010; 102 (16): 1238-52
3. van Ballegooijen M, Habbema JDF, Boer R, Zauber AG, Brown ML,. Report to the Agency for Healthcare Research and Quality: A comparison of the cost-effectiveness of fecal occult blood tests with different test characteristics in the context of annual screening in the Medicare population., 2003. Available from: http://www.cms.gov/medicare-coverage-database/details/technology-Assessments-details.aspx?TAId=20
4. Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, Wilschut J, van Ballegooijen M, Kuntz KM,. Evaluating test strategies for colorectal cancer screening: A decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med. 2008; 149 (9): 659-69
5. USPSTF. Screening for colorectal cancer: recommendation and rationale. Ann Intern Med. 2002; 137 (2): 129-31
6. Rutter CM, Zaslavsky AM, Feuer EJ,. Dynamic microsimulation models for health outcomes: A review. Med Decis Making. 2010; 31 (1): 10-8
7. Rutter CM, Yu O, Miglioretti DL,. A hierarchical non-homogenous Poisson model for meta-Analysis of adenoma counts. Stat Med. 2007; 26 (1): 98-109
8. Ries LAG, Kosary CL, Hankey BF, Miller BA, Edwards BK, eds. SEER Cancer Statistics Review, 1973-1995. Bethesda, MD: National Cancer Institute; 1998
9. Whitlock EP, Lin JS, Liles E, Beil TL, Fu R,. Screening for colorectal cancer: A targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2008; 149 (9): 638-58
10. Stout NK, Knudsen AB, Kong CY, McMahon PM, Gazelle GS,. Calibration methods used in cancer simulation models and suggested reporting guidelines. Pharmacoeconomics. 2009; 27 (7): 533-45
11. Jackson CH, Jit M, Sharples LD, De Angelis D,. Calibration of complex models through bayesian evidence synthesis: A demonstration and tutorial. Med Decis Making. 2015; 35 (2): 148-61
12. Eddy DM, Hollingworth W, Caro JJ, et al. Model transparency and validation: A report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7. Med Decis Making. 2012; 32 (5): 733-43
13. Afzali HH, Gray J, Karnon J,. Model performance evaluation (validation and calibration) in model-based studies of therapeutic interventions for cardiovascular diseases: A review and suggested reporting framework. Appl Health Econ Health Policy. 2013; 11 (2): 85-93
14. Rutter CM, Miglioretti DL, Savarino JE,. Bayesian calibration of microsimulation models. J Am Stat Assoc. 2009; 104 (488): 1338-50
15. Rutter CM, Savarino JE,. An evidence-based microsimulation model for colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2010; 19 (8): 1992-2002
16. Kuntz KM, Lansdorp-Vogelaar I, Rutter CM, et al. A systematic comparison of microsimulation models of colorectal cancer: The role of assumptions about adenoma progression. Med Decis Making. 2011; 31 (4): 530-9
17. van Ballegooijen M, Rutter CM, Knudsen AB, et al. Clarifying differences in natural history between models of screening: The case of colorectal cancer. Med Decis Making. 2011; 31 (4): 540-9
18. Weiss NS,. Case-control studies of the efficacy of screening tests designed to prevent the incidence of cancer. Am J Epidemiol. 1999; 149 (1): 1-4
19. Atkin WS, Cook CF, Cuzick J, et al. Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial. Lancet. 2002; 359 (9314): 1291-300
20. Atkin WS, Edwards R, Kralj-Hans I, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: A multicentre randomised controlled trial. Lancet. 2010; 375 (9726): 1624-33
21. Frazier AL, Colditz GA, Fuchs CS, Kuntz KM,. Cost-effectiveness of screening for colorectal cancer in the general population. JAMA. 2000; 284 (15): 1954-61
22. Loeve F, Boer R, van Oortmarssen GJ, van Ballegooijen M, Habbema JD,. The MISCAN-COLON simulation model for the evaluation of colorectal cancer screening. Comput Biomed Res. 1999; 32 (1): 13-33
23. CISNET. 2014 [cited 2014 30 ]. Available from: http://cisnet.cancer.gov
24. National Center for Health Statistics. US Life Tables 2000. Available from: http://www.cdc.gov/nchs/products/pubs/pubd/lftbls/life/1966.htm
25. Rutter CM, Johnson EA, Feuer EJ, Knudsen AB, Kuntz KM, Schrag D,. Secular trends in colon and rectal cancer relative survival. J Natl Cancer Inst. 2013; 105 (23): 1806-13
26. Kalbfleisch JD, Prentice RL,. The statistical analysis of failure time data. New York: John Wiley; 1980
27. Wardle J, Miles A, Atkin W,. Gender differences in utilization of colorectal cancer screening. J Med Screen. 2005; 12: 20-7
28. Painter J, Saunders DB, Bell GD, Williams CB, Pitt R, Bladen J,. Depth of insertion at flexible sigmoidoscopy: implications for colorectal cancer screening and instrument design. Endoscopy. 1999; 31 (3): 227-31
29. van Rijn JC, Reitsma JB, Stoker J, Bossuyt PM, van Deventer SJ, Dekker E,. Polyp miss rate determined by tandem colonoscopy: A systematic review. Am J Gastroenterol. 2006; 101 (2): 343-50
30. Atkin WS, Valori R, Kuipers EJ, et al. European guidelines for quality assurance in colorectal cancer screening and diagnosis. First edition-colonoscopic surveillance following adenoma removal. Endoscopy. 2012; 44 (Suppl 3): SE151-63
31. van Hees D, Habbemma J, Meester R, Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG,. Should colorectal cancer screening be considered in elderly persons without previous screening? a cost-effectiveness analysis. Ann Intern Med. 2014; 160 (11): 750-9
32. Berg JW, Downing A, Lukes RJ,. Prevalence of undiagnosed cancer of the large bowel found at autopsy in different races. Cancer. 1970; 25 (5): 1076-80
33. Carethers JM,. One colon lumen but two organs. Gastroenterology. 2011; 141 (2): 411-2
34. Burnett-Hartman AN, Newcomb PA, Phipps AI, et al. Colorectal endoscopy, advanced adenomas, and sessile serrated polyps: implications for proximal colon cancer. Am J Gastroenterol. 2012; 107 (8): 1213-9
35. Brenner H, Chang-Claude J, Jansen L, Seiler CM, Hoffmeister M,. Role of colonoscopy and polyp characteristics in colorectal cancer after colonoscopic polyp detection: A population-based case-control study. Ann Intern Med. 2012; 157 (4): 225-32
36. Baxter NN, Warren JL, Barrett MJ, Stukel TA, Doria-Rose VP,. Association between colonoscopy and colorectal cancer mortality in a US cohort according to site of cancer and colonoscopist specialty. J Clin Oncol. 2012; 30 (21): 2664-9
37. Doubeni CA, Weinmann S, Adams K, et al. Screening colonoscopy and risk for incident late-stage colorectal cancer diagnosis in average-risk adults: A nested case-control study. Ann Intern Med. 2013; 158 (5 Pt 1): 312-20
38. Brenner H, Hoffmeister M, Volker A, Stegmaier C, Altenhofen L, Haug U,. Protection from right-and left-sided colorectal neoplasms after colonoscopy: population-based study. J Natl Cancer Inst. 2010; 102 (2): 89-95
39. Rex DK, Ahnen DJ, Baron JA, et al. Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol. 2012; 107 (9): 1315-29; quiz 4, 30
40. Chokshi RV, Hovis CE, Hollander T, Early DS, Wang JS,. Prevalence of missed adenomas in patients with inadequate bowel preparation on screening colonoscopy. Gastrointest Endosc. 2012; 75 (6): 1197-203
41. Chiu HM, Lin JT, Lee YC, et al. Different bowel preparation schedule leads to different diagnostic yield of proximal and nonpolypoid colorectal neoplasm at screening colonoscopy in average-risk population. Dis Colon Rectum. 2011; 54 (12): 1570-7
42. Hoeting JA, Madigan D, Raftery AE, Volinsky CT,. Bayesian model averaging: A tutorial. (vol 14, pg 382, 1999). Stat Sci. 2000; 15 (3): 193-5
43. de Koning HJ, Meza R, Plevritis SK, et al. Benefits and harms of computed tomography lung cancer screening strategies: A comparative modeling study for the U.S. Preventive Services Task Force. Ann Intern Med. 2014; 160 (5): 311-20
44. Lindstrom T, Tildesley M, Webb C,. A Bayesian ensemble approach for epidemiological projections. PLoS Comput Biol. 2015; 11 (4): e1004187
45. Banks J, Muriel A, Smith JP,. Disease prevalence, disease incidence, and mortality in the United States and in England. Demography. 2010; 47 (Suppl): S211-31
46. Pinsky PF, Miller A, Kramer BS, et al. Evidence of a healthy volunteer effect in the prostate, lung, colorectal, and ovarian cancer screening trial. Am J Epidemiol. 2007; 165 (8): 874-81.